Susquehanna International Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Susquehanna International Group’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$875K	Buy	560,700 +360,800	+180%	+$525K	﹤0.01%	8233
2025 Q4	$230K	Buy	199,900 +84,100	+73%	+$116K	﹤0.01%	10561
2025 Q3	$156K	Sell	115,800 -6,000	-5%	-$6.81K	﹤0.01%	11243
2025 Q2	$116K	Buy	121,800 +75,700	+164%	+$49K	﹤0.01%	11702
2025 Q1	$21.2K	Buy	+46,100	New	+$29.1K	﹤0.01%	12097
2024 Q4	–	Sell	-427,600	Closed	-$671K	–	12793
2024 Q3	$671K	Sell	427,600 -127,800	-23%	-$228K	﹤0.01%	7767
2024 Q2	$933K	Sell	555,400 -1,416,800	-72%	-$2.54M	﹤0.01%	6757
2024 Q1	$4.73M	Buy	1,972,200 +1,931,000	+4,687%	+$4.15M	﹤0.01%	3712
2023 Q4	$63K	Sell	41,200 -11,200	-21%	-$13.3K	﹤0.01%	11610
2023 Q3	$57.1K	Buy	52,400 +40,400	+337%	+$70.9K	﹤0.01%	11238
2023 Q2	$27.5K	Sell	12,000 -76,000	-86%	-$202K	﹤0.01%	11550
2023 Q1	$214K	Buy	88,000 +21,000	+31%	+$48.1K	﹤0.01%	10456
2022 Q4	$128K	Buy	67,000 +34,300	+105%	+$73K	﹤0.01%	10694
2022 Q3	$78K	Sell	32,700 -28,500	-47%	-$78.9K	﹤0.01%	11910
2022 Q2	$114K	Buy	+61,200	New	+$117K	﹤0.01%	11346
2022 Q1	–	Sell	-13,900	Closed	-$55K	–	13573
2021 Q4	$55K	Sell	13,900 -19,700	-59%	-$95.7K	﹤0.01%	12499
2021 Q3	$162K	Sell	33,600 -99,400	-75%	-$408K	﹤0.01%	11727
2021 Q2	$610K	Sell	133,000 -69,500	-34%	-$335K	﹤0.01%	9109
2021 Q1	$1.19M	Sell	202,500 -203,200	-50%	-$1.41M	﹤0.01%	7261
2020 Q4	$1.39M	Buy	405,700 +309,300	+321%	+$590K	﹤0.01%	5915
2020 Q3	$139K	Buy	96,400 +41,200	+75%	+$73.3K	﹤0.01%	9735
2020 Q2	$110K	Sell	55,200 -38,800	-41%	-$76K	﹤0.01%	9453
2020 Q1	$183K	Sell	94,000 -154,900	-62%	-$461K	﹤0.01%	8792
2019 Q4	$1.03M	Buy	248,900 +15,300	+7%	+$58.9K	﹤0.01%	5456
2019 Q3	$703K	Buy	233,600 +168,700	+260%	+$522K	﹤0.01%	6526
2019 Q2	$408K	Sell	64,900 -35,200	-35%	-$211K	﹤0.01%	7694
2019 Q1	$557K	Buy	+100,100	New	+$608K	﹤0.01%	6053
2018 Q4	–	Sell	-55,500	Closed	-$592K	–	9525
2018 Q3	$592K	Buy	55,500 +1,000	+2%	+$11.5K	﹤0.01%	6224
2018 Q2	$654K	Buy	54,500 +33,300	+157%	+$341K	﹤0.01%	6273
2018 Q1	$182K	Sell	21,200 -73,000	-77%	-$675K	﹤0.01%	8390
2017 Q4	$931K	Sell	94,200 -2,200	-2%	-$22.9K	﹤0.01%	5384
2017 Q3	$1.19M	Buy	96,400 +75,200	+355%	+$1.11M	﹤0.01%	4966
2017 Q2	$349K	Sell	21,200 -73,700	-78%	-$1.14M	﹤0.01%	7301
2017 Q1	$1.36M	Buy	94,900 +17,900	+23%	+$266K	﹤0.01%	4482
2016 Q4	$1.06M	Sell	77,000 -102,100	-57%	-$1.64M	﹤0.01%	5399
2016 Q3	$3.24M	Sell	179,100 -92,400	-34%	-$1.49M	﹤0.01%	2790
2016 Q2	$3.9M	Buy	271,500 +226,000	+497%	+$3.07M	﹤0.01%	2548
2016 Q1	$544K	Sell	45,500 -23,700	-34%	-$248K	﹤0.01%	6248
2015 Q4	$921K	Buy	69,200 +39,500	+133%	+$486K	﹤0.01%	5577
2015 Q3	$319K	Buy	+29,700	New	+$324K	﹤0.01%	7931

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group's LXRX Position: Q1 2026 in Review

Susquehanna International Group increased its Lexicon Pharmaceuticals (LXRX) stake by 76% in Q1 2026, buying an estimated $1.33M and bringing the position to 2,121,164 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #5065.

Susquehanna International Group first reported a position in LXRX in Q2 2013 and has held it in 45 quarters since. The position peaked at $6.99M in Q2 2017. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

Susquehanna International Group held 2,121,164 shares of Lexicon Pharmaceuticals worth $3.31M as of Q1 2026.
Susquehanna International Group bought 913,922 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $1.33M.
Lexicon Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5065 holding.
Susquehanna International Group first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
Susquehanna International Group's Lexicon Pharmaceuticals position peaked at $6.99M in Q2 2017.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.